ABUS — ARBUTUS BIOPHARMA CORP
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
Why are billionaires buying ABUS?
Built from public SEC filings and public economic data. Not a recommendation.
Why? — Evidence & Confidence ▾
Of 2 tracked investors who changed their ABUS position last quarter, 1 bought and 1 sold (50% buy-side). Macro conditions are a headwind for this sector (Macro Tailwind 38/100 in a Expansion regime).
- +1 tracked investor added or increased positions last quarter (Izzy Englander)
- +2 tracked investors reported holding ABUS at their latest filing
- −1 tracked investor reduced or exited last quarter (1 reduced, 0 sold out)
- −Current Expansion regime has historically been a headwind for this sector (Macro Tailwind 38/100)
- −13F data is disclosed up to 45 days after quarter end — positions may have changed since
- · 13F disclosure lag (up to 45 days)
- · Tracked investors are a sample, not the whole market
- · Sector regime fit is a historical average, not a guarantee
Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 11/22/2026.
About ARBUTUS BIOPHARMA CORP (ABUS)
ARBUTUS BIOPHARMA CORP (ABUS) appears in the most recent 13F filings of 2 tracked institutional investors. The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $15M. Across recent filings, tracked investors recorded 4 new positions, 6 increased, 3 reduced, and 3 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in ABUS
How many top investors track ABUS
Only 2 tracked investors report this position.
ABUS Ownership Composition
How ARBUTUS BIOPHARMA CORP is held across tracked investor types, based on reported 13F positions.
- Multi-Strategy / Quant100.0%
Tracked investors currently reporting ABUS
- Izzy EnglanderSep 30, 2026Millennium ManagementShares3.1MValue$14.6M% Portfolio0.00%
- Ken GriffinSep 30, 2026Citadel AdvisorsShares179.9KValue$860K% Portfolio0.00%
Recent activity
- $14.6MNov 16, 2026
- Reduced$860K(-55.54%)Nov 16, 2026
- Increased$966.2K(20.09%)Nov 14, 2024
- Increased$1.1M(36.69%)Feb 14, 2025
- Increased$1.2M(1.51%)May 15, 2025
- Increased$1.5M(43.44%)Aug 14, 2025
- Sold$0(-100.00%)Feb 17, 2026
- $2.9MMay 15, 2026
- Sold$0(-100.00%)Aug 14, 2026
- Increased$2.7M(251.55%)Nov 14, 2024
- Reduced$750.1K(-40.31%)May 15, 2025
- Increased$703.8K(5.98%)Aug 14, 2025
- Sold$0(-100.00%)Nov 14, 2025
- Reduced$1.9M(-48.46%)Aug 14, 2026
- New$613.3KAug 14, 2024
- $624.9KMay 15, 2024
Frequently asked questions
- How many institutional investors hold ABUS?
- 2 tracked institutional investors disclosed a position in ABUS (ARBUTUS BIOPHARMA CORP) in their most recent 13F filing.
- Who is the largest institutional holder of ABUS?
- Izzy Englander, Millennium Management, holds the largest disclosed position in ABUS, valued at $15M.
- Did institutional ownership of ABUS increase or decrease?
- Across recent 13F filings, tracked investors recorded 4 new positions, 6 increased, 3 reduced, and 3 fully exited ABUS.
- Where does this ABUS ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.